Opportunities arise for once-spurned partners
Following the Pfizer-Biohaven blueprint, could other licensing deals turn into buyouts?
Bristol needs to get fresh
Move over Amgen – Bristol Myers Squibb now looks like the big biopharma group most in need of revitalisation.
Biogen says goodbye to Vounatsos and remaining Aduhelm hopes
The company's chief executive pays for the Aduhelm fiasco, but who will want to step up and take on the Biogen challenge?
Late-stage pain pipeline refuses to swell
Setbacks from Eliem, Ampio and Acadia thin an already sparse pain pipeline, which remains lacking in serious interest from big developers.
Is biopharma getting better at accelerated approval conversions?
Amid ongoing pressure to reform the FDA’s fast-track pathway, signs emerge that the criticism is being heard.
